share_log

The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts

The Analyst Verdict: Gilead Sciences In The Eyes Of 12 Experts

分析师的判决:12位专家眼中的吉利德科学
Benzinga ·  04/19 15:00
In the last three months, 12 analysts have published ratings on Gilead Sciences (NASDAQ:GILD), offering a diverse range of perspectives from bullish to bearish.
在过去的三个月中,有12位分析师公布了对吉利德科学(纳斯达克股票代码:GILD)的评级,提供了从看涨到看跌的不同视角。
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
下表总结了他们最近的评级,展示了过去30天内不断变化的情绪,并将其与前几个月进行了比较。
Analysts have recently evaluated Gilead Sciences and provided 12-month price targets. The average target is $84.42, accompanied by a high estimate of $105.00 and a low estimate of $75.00. This current average represents a 5.15% decrease from the previous average price target of $89.00.
分析师最近对吉利德科学进行了评估,并提供了12个月的价格目标。平均目标为84.42美元,最高估计值为105.00美元,低估值为75.00美元。目前的平均价格比之前的平均目标价89.00美元下降了5.15%。
Investigating Analyst Ratings: An Elaborate Study
调查分析师评级:一项详尽的研究
The analysis of recent analyst actions sheds light on...
对分析师近期行为的...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发